Pure Biologics S.A. (FRA:PQB)

Market Cap	7.87M -43.1%
Revenue (ttm)	n/a
Net Income	-4.20M
EPS	-1.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	0.5475
Previous Close	0.5600
Day's Range	0.5475 - 0.5475
52-Week Range	0.5395 - 3.4400
Beta	n/a
RSI	30.67
Earnings Date	Apr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PQB

Financial Performance

Financial numbers in PLN